Across TCGA pan-cancer cohorts, PHETA1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHETA1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher PHETA1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHETA1 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

PRAD, UCEC, and LUAD are the cancer types where PHETA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.236	0.788	.006	6	view →
SCLC	DFS	Median	All	1.000	0.216	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PHETA1 tumor-vs-normal RNA expression · all PHETA1 data types